APA (7th ed.) Citation

N, C., Z, W., AJ, I., JA, Z., E, S., RJ, G., . . . KT, F. (2026). Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(7), 1224. https://doi.org/10.1158/1078-0432.CCR-25-1247

Chicago Style (17th ed.) Citation

N, Coleman, et al. "Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 32, no. 7 (2026): 1224. https://doi.org/10.1158/1078-0432.CCR-25-1247.

MLA (9th ed.) Citation

N, Coleman, et al. "Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 32, no. 7, 2026, p. 1224, https://doi.org/10.1158/1078-0432.CCR-25-1247.